drugset / Trial / NCT00047281
Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma
Phase 2
Completed
Dana-Farber Cancer Institute
Celgene Corporation · collabNational Cancer Institute (NCI) · collabSchering-Plough · collab
Open-labelTreatment
Summary
RATIONALE: Thalidomide and celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining thalidomide and celecoxib with etoposide and cyclophosphamide may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining thalidomide and celecoxib with etoposide and cyclophosphamide in treating patients who have relapsed or refractory malignant glioma.
Timeline
- Start
- 2004-03
- Primary completion
- 2005-08
- Completion
- 2006-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Celecoxib | Other / unclassified | — | Oral |
| Subject | Cyclophosphamide | Other / unclassified | — | Oral |
| Subject | Etoposide | Small molecule | — | Oral |
| Subject | Thalidomide | Other / unclassified | — | Oral |